Please login to the form below

Not currently logged in
Email:
Password:

GRI

This page shows the latest GRI news and features for those working in and with pharma, biotech and healthcare.

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Ziylo could help it stay ahead in key insulin franchise. Novo Nordisk is aiming to develop the world’s first glucose responsive insulin (GRI) by acquiring UK biotech start-up Ziylo.

Latest news

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    TiGenix’ board is backing the takeover deal, which values the company at 520m (around $630m), and two major shareholders - Gri-Cel and Grifols - have already said they will tender their shares.

  • No man is an island

    Perhaps the most high-profile example of these is the Global Reporting Initiative (GRI), which now has 50 pharmaceutical and biotech companies among its 1, 000-plus registered organisations.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....